Literature DB >> 16330103

Pro- and anti-inflammatory cytokines in the CSF of patients with Creutzfeldt-Jakob disease.

Katharina Stoeck1, Monika Bodemer, Inga Zerr.   

Abstract

We investigated cerebrospinal fluid (CSF) samples from patients with Creutzfeldt-Jakob disease (CJD) and other neurological diseases. Concentrations of pro- and anti-inflammatory cytokines IL-1beta, IL-6, IL-8, IL-12, TNF-alpha and TGF-beta 2 were determined in CSF using ELISA. Significant changes were found for IL-8 and TGF-beta 2. IL-8 levels were elevated in the CSF of CJD patients. Of interest, the increase was significant to other dementia and to controls. In contrast, TGF-beta 2 was significantly decreased in CSF of CJD compared to all groups. IL-1beta, IL-12 and TNF-alpha could not be detected in CSF or in case of IL-6 in only low concentrations without significant difference.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330103     DOI: 10.1016/j.jneuroim.2005.10.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Detection of anti-glutamate receptor ε2 and anti-N-methyl-D: -aspartate receptor antibodies in a patient with sporadic Creutzfeldt-Jakob disease.

Authors:  Koji Fujita; Tatsuhiko Yuasa; Yukitoshi Takahashi; Keiko Tanaka; Shuji Hashiguchi; Katsuhito Adachi; Yuishin Izumi; Ryuji Kaji
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

2.  Rapidly progressive Creutzfeldt-Jakob disease in patients with Familial Mediterranean Fever.

Authors:  S A Appel; J Chapman; E Kahana; H Rosenmann; I Prohovnik; E Pras; H Reznik-Wolf; O S Cohen
Journal:  Eur J Neurol       Date:  2010-01-20       Impact factor: 6.089

3.  An In Vivo 11C-(R)-PK11195 PET and In Vitro Pathology Study of Microglia Activation in Creutzfeldt-Jakob Disease.

Authors:  Leonardo Iaccarino; Rosa Maria Moresco; Luca Presotto; Orso Bugiani; Sandro Iannaccone; Giorgio Giaccone; Fabrizio Tagliavini; Daniela Perani
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

4.  Creutzfeldt-Jakob disease after COVID-19: infection-induced prion protein misfolding? A case report.

Authors:  Andrea Bernardini; Gian Luigi Gigli; Francesco Janes; Gaia Pellitteri; Chiara Ciardi; Martina Fabris; Mariarosaria Valente
Journal:  Prion       Date:  2022-12       Impact factor: 2.547

5.  Thermodynamic and structural characterization of an antibody gel.

Authors:  Osigwe Esue; Anna X Xie; Tim J Kamerzell; Thomas W Patapoff
Journal:  MAbs       Date:  2013-02-20       Impact factor: 5.857

6.  Genomic and post-genomic analyses of human prion diseases.

Authors:  Maurizio Pocchiari; Anna Poleggi; Serena Principe; Silvia Graziano; Franco Cardone
Journal:  Genome Med       Date:  2009-06-22       Impact factor: 11.117

Review 7.  β-amyloid, microglia, and the inflammasome in Alzheimer's disease.

Authors:  Maike Gold; Joseph El Khoury
Journal:  Semin Immunopathol       Date:  2015-08-07       Impact factor: 9.623

8.  Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease.

Authors:  Anna Bartoletti-Stella; Patrizia Corrado; Nicola Mometto; Simone Baiardi; Pascal F Durrenberger; Thomas Arzberger; Richard Reynolds; Hans Kretzschmar; Sabina Capellari; Piero Parchi
Journal:  Mol Neurobiol       Date:  2018-11-16       Impact factor: 5.590

9.  Changes in gene expression of DOR and other thyroid hormone receptors in rat liver during acute-phase response.

Authors:  Ihtzaz Ahmed Malik; Bernhard G Baumgartner; Naila Naz; Nadeem Sheikh; Federico Moriconi; Giuliano Ramadori
Journal:  Cell Tissue Res       Date:  2010-10-15       Impact factor: 5.249

10.  MicroRNA 146a (miR-146a) is over-expressed during prion disease and modulates the innate immune response and the microglial activation state.

Authors:  Reuben Saba; Shantel Gushue; Rhiannon L C H Huzarewich; Kathy Manguiat; Sarah Medina; Catherine Robertson; Stephanie A Booth
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.